Better late than never Skinbiotherapeutics (SBTX) has served up a (piss poor) delayed trading update and declined to offer specific guidance going forward other than to ‘fess that it is still loss making and burning cash. It has not yet secured anyone prepared to act as NED as it stated it would by mid September so what’s the good news?
On 24 August 2026 as Skinbiotherapeutics (SBTX) appointed a new interim CFO to replace the hapless Emily Bertram it stated “The Company is in advanced discussions with potential NED candidates and looks forward to updating the market in due course, and is also intending to issue a business update by mid-September which will include further Board updates.”
"You are not answering the f*cking question" I screamed at my screen as Alyson Levett failed to answer one of the questions I posed. Up until that point I was really quite impressed. So what are the key takeaways from today’s Investor Meet event.
First it was the prolific liar and fraudster Stuart Ashman, then the incompetent chairman Martin Hunt and now I have a third scalp: Emily Bertram who was appointed as CFO in April 2025 and joined the board in January 2026 has resigned from Skinbiotherapeutics (SBTX) and will leave the company next Tuesday. Another head I demanded has rolled.
Quite rightly most questions submitted to the Investor Meet platform ahead of the rampfest will be about forward guidance: what is the cash position now at Skinbiotherapeutics (SBTX), what is the cash burn, what are revised FY 2026 and 2027 estimates etc. But as a non shareholder and a nerd I have different questions that I have now submitted with no expectation at all of them being answered. I have asked:
Some folks are prolific liars. Some folks cheer on prolific liars and some folks get attacked for being a good guy who exposes prolific liars. If you believe that I am the source of all evil like crazy Meg Short at Bloomberg and so deserve to be “destroyed”, here is yet more evidence that I am a good guy and that you are just plain wrong and stupid and a disgrace to your profession.
As I have noted many times, to hoots of derision from small furry rodents, Stuart Ashman’s fanboys and other denialists, if the only matter being investigated by FRP at Skinbiotherapeutics (SBTX) was the fraudulent recognition of accrued income from Croda, thus investigation which started in mid February would have been over by March. Today we have an update.
A TR1 is just up, the purchaser of the 8.9 million Skinbiotherapeutics (SBTX) dumped by Police Time Wastin’ Steve O’Hara’s Optibiotix, is, as I predicted, that Mark Dixon fellow. He paid 9p for the shares so is averaging down/catching a falling knife.
I have a framed letter ( he framed it) from Skinbiotherapeutics (SBTX) lunatic Bill Barbour explaining why I should not sell my shares because they were going to at least ten quid each. Of course Bill sold his shares at 14p. The shares were suspended at 9.75p.
On April Fool’s day shares in Skinbiotherapeutics (SBTX) were suspended as it was unable to publish its results for the 6 months to December 2025 as FRP advisory continued its investigations into FRAUD. Yes D&D I did say FRAUD.
A few readers pose the question. Shares in Skinbiotherapeutics (SBTX) have now been suspended for almost three weeks as a result of it not being able to get out its accounts for the six months to December 31 while enquiries continue into the fraudulent June 2025 numbers. But why is this taking so long?
There are those "experts" who will still tell you that all is well at Skinbiotherapeutics (SBTX), we know the full extent of the fraud and that we will get results in April confirming we will soon enter the Croda sunlit uplands. Are the "experts" who used to eat out of the hand of Ashman really sure? They may be right, thus time, but...
It is almost certain that the Financial Reporting Council will be conducting its own enquiry into the fraudulent June 2025 accounts of Skinbiotherapeutics (SBTX). I have reported the company, its auditors Gravita and audit partner Jan Charlesworth to my good pals at the FRC but there are two updates…
Any suggestion from the denialists that Skinbiotherapeutics (SBTX) might have over egged the extent of the crimes of disgraced prolific liar and fraudster Stuart Ashman and that there might be a kiss and make up are today put to bed with news that Rachel Parsonage has been appointed as interim CEO. She appears to have a cracking CV but..
